文献速递神经MR

锰增强MRI在多发性硬化患者中的应用

Manganese-Enhanced MRI in Patients with Multiple Sclerosis.
PubMed 文献 · AJNR Am J Neuroradiol · 2020-08-06

本研究为6例成人多发性硬化患者的病例系列,基线行钆增强扫描后注射锰螯合物锰福地吡并多时间点随访。研究期间形成14个新病灶,其中10个显示强度、时间及空间模式各异的锰增强;锰增强可见于注射后数天形成的病灶并持续数周,部分病灶锰增强范围大于钆增强和T2-FLAIR异常范围。作者认为这是锰对比剂首次用于增强多发性硬化病灶,其时空特征与钆不同,机制及细胞特异性摄取需进一步实验。

要点

  • 锰增强可显示多发性硬化新病灶,增强强度、时间及空间模式多样。
  • 锰增强可见于注射后数天形成的病灶,并持续数周,提示细胞内摄取。
  • 部分病灶锰增强范围大于钆增强和T2-FLAIR异常范围。

核心结论

  • 本研究首次使用锰对比剂在MRI上增强多发性硬化病灶,其时间与空间特征不同于钆增强。
  • 锰增强的机制及细胞特异性摄取尚需进一步实验阐明。

研究设计与样本

  • 病例系列,纳入6例成人多发性硬化患者。
  • 基线行钆增强扫描,随后注射锰螯合物锰福地吡,并在此后不同时间点随访。

关键影像表现/征象

  • 研究期间形成14个新病灶,其中10个显示强度、时间及空间模式各异的锰增强。
  • 1个钆增强的轴外肿块(推测为脑膜瘤)也显示锰增强。
  • 锰增强可见于锰福地吡注射后数天形成的病灶,并持续数周,符合对比剂来自锰的细胞内摄取。
  • 部分病灶显示锰增强呈弥漫模式,范围大于钆增强和T2-FLAIR信号异常范围。

局限性

  • 需进一步实验以阐明锰对比增强的机制及细胞特异性摄取。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Cellular uptake of the manganese ion, when administered as a contrast agent for MR imaging, can noninvasively highlight cellular activity and disease processes in both animals and humans. The purpose of this study was to explore the enhancement profile of manganese in patients with multiple sclerosis.

MATERIALS AND METHODS: Mangafodipir is a manganese chelate that was clinically approved for MR imaging of liver lesions. We present a case series of 6 adults with multiple sclerosis who were scanned at baseline with gadolinium, then injected with mangafodipir, and followed at variable time points thereafter.

RESULTS: Fourteen new lesions formed during or shortly before the study, of which 10 demonstrated manganese enhancement of varying intensity, timing, and spatial pattern. One gadolinium-enhancing extra-axial mass, presumably a meningioma, also demonstrated enhancement with manganese. Most interesting, manganese enhancement was detected in lesions that formed in the days after mangafodipir injection, and this enhancement persisted for several weeks, consistent with contrast coming from intracellular uptake of manganese. Some lesions demonstrated a diffuse pattern of manganese enhancement in an area larger than that of both gadolinium enhancement and T2-FLAIR signal abnormality.

CONCLUSIONS: This work demonstrates the first use of a manganese-based contrast agent to enhance MS lesions on MR imaging. Multiple sclerosis lesions were enhanced with a temporal and spatial profile distinct from that of gadolinium. Further experiments are necessary to uncover the mechanism of manganese contrast enhancement as well as cell-specific uptake.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Suto DJ, Nair G, Sudarshana DM, et al. Manganese-Enhanced MRI in Patients with Multiple Sclerosis. AJNR Am J Neuroradiol. 2020. PMID: 32763897. doi:10.3174/ajnr.A6665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。